AACR 2024First-In-human, Dose Escalation and Expansion Study of MT-6402, a Novel Engineered Toxin Body (ETB) Targeting PD-L1, in Patients with Relapsed/Refractory Advanced Solid Tumors: Interim Data
Lymphoma, Leukemia, & Myeloma Congress 2023 A First-in-Human Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of MT-0169, a CD38-targeting Engineered Toxin Body (ETB), in Relapsed or Refractory Multiple Myeloma
AACR 2023Engineered Toxin Bodies (ETBs): Clinical stage immunotoxins with a safer and differentiated profile
San Antonio Breast Cancer Symposium 2022 A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+ tumors: interim results
2022 SITC #736 A clinical stage engineered toxin body (ETB) targeting PD-L1 (MT-6402) induces peripheral pharmacodynamic responses unique from PD-L1 monoclonal antibodies
2022 SITC #764 First-in-human, dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/refractory advanced solid tumors: Interim Data
2022 SITC #817 Engineered toxin body targeting CTLA-4 (MT-8421) depletes Tregs in the tumor microenvironment and synergizes with αPD-1 to enhance T cell immunity
2022 SITC #1379 Engineered toxin body targeting TIGIT depletes Tregs in the tumor microenvironment and reduces tumor burden in mice
